Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption

A single-center, open-label, three-way crossover study was conducted in 24 healthy subjects to assess (1) the bioequivalence of a combined lamivudine 150 mg/zidovudine 300 mg tablet relative to the separate brand-name components administered concurrently and (2) the effect of food on the bioavailability of the drugs from the combination tablet. The subjects were randomly assigned to receive each of the following three treatments, separated by a 5- to 7-day washout period: one lamivudine/zidovudine combination tablet after an overnight fast, one lamivudine 150 mg tablet and one zidovudine 300 mg tablet simultaneously after an overnight fast, or one lamivudine/zidovudine combination tablet 5 minutes after completing a standardized high-fat breakfast (67 g fat, 58 g carbohydrate, and 33 g protein). Serial blood samples were collected up to 24 hours postdose for the determination of lamivudine and zidovudine plasma concentrations. Standard pharmacokinetic parameters were estimated. Treatments were considered bioequivalent if 90% confidence intervals for the ratio of least squares (LS) means for the lamivudine and zidovudine area under the plasma concentration-time curve (AUC infinity) and maximum observed plasma concentration (Cmax) fell entirely within 0.80 to 1.25 for log-transformed parameters. The combined lamivudine/zidovudine tablet was bioequivalent in the extent (AUC infinity) and rate of absorption (Cmax and time of Cmax [tmax]) to the individual brand-name drug components administered concurrently under fasted conditions. Geometric LS mean ratios and 90% confidence intervals for AUC infinity and Cmax were 0.97 (0.92, 1.03) and 0.94 (0.84, 1.06), respectively, for lamivudine and 0.99 (0.91, 1.07) and 0.97 (0.82, 1.15), respectively, for zidovudine. The extent of absorption of lamivudine and zidovudine from the combination tablet was not altered by administration with meals, indicating that this formulation may be administered with or without food. However, food slowed the rate of absorption, delayed the tmax, and reduced the Cmax of lamivudine and zidovudine. These changes were not considered clinically important. All formulations were well tolerated under fasted and fed conditions.

This article has been cited by other articles:

				J. F. Marier, M. DiMarco, R. Guilbaud, C. Dodard, G. Morelli, S. K. Tippabhotla, A. K. Singla, N. R. Thudi, and T. Monif Pharmacokinetics of Lamivudine, Zidovudine, and Nevirapine Administered as a Fixed-Dose Combination Formulation Versus Coadministration of the Individual Products J. Clin. Pharmacol., November 1, 2007; 47(11): 1381 - 1389. [Abstract] [Full Text] [PDF]

				X.-J. Zhou, D. M. Lloyd, G. C. Chao, and N. A. Brown Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J. Clin. Pharmacol., March 1, 2006; 46(3): 275 - 281. [Abstract] [Full Text] [PDF]

				V. S. Narang, A. Lulla, G. Malhotra, and S. Purandare A Combined-Formulation Tablet of Lamivudine/Nevirapine/Stavudine: Bioequivalence Compared With Concurrent Administration of Lamivudine, Nevirapine, and Stavudine in Healthy Indian Subjects J. Clin. Pharmacol., March 1, 2005; 45(3): 265 - 274. [Abstract] [Full Text] [PDF]

				G. J. Yuen, Y. Lou, N. F. Bumgarner, J. P. Bishop, G. A. Smith, V. R. Otto, and D. D. Hoelscher Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily Antimicrob. Agents Chemother., January 1, 2004; 48(1): 176 - 182. [Abstract] [Full Text] [PDF]

				H. L. Jordan, A. S. Pereira, M. S. Cohen, and A. D. M. Kashuba Domestic Cat Model for Predicting Human Nucleoside Analogue Pharmacokinetics in Blood and Seminal Plasma Antimicrob. Agents Chemother., July 1, 2001; 45(7): 2173 - 2176. [Abstract] [Full Text] [PDF]

				T. N. Kakuda, L. M. Page, P. L. Anderson, K. Henry, T. W. Schacker, F. S. Rhame, E. P. Acosta, R. C. Brundage, and C. V. Fletcher Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir Antimicrob. Agents Chemother., January 1, 2001; 45(1): 236 - 242. [Abstract] [Full Text]

				K. H. P. Moore, G. J. Yuen, E. K. Hussey, G. E. Pakes, J. J. Eron Jr., and J. A. Bartlett Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials Antimicrob. Agents Chemother., December 1, 1999; 43(12): 3025 - 3029. [Abstract] [Full Text]